Navigation Links
UPDATED: Evalve(R) Completes $60 Million Series D Financing
Date:12/4/2007

ation (MR), the most common type of heart valve insufficiency occurs when the heart's mitral valve does not close properly. Both the American Heart Association and the American College of Cardiology recommend open-heart surgery to repair or replace the mitral valve for patients who suffer from moderate-to-severe (Grade 3+) and severe (Grade 4+) MR; open heart surgery is not recommended for patients with 1-2+ MR. An estimated four million people in the United States have significant (greater than 2+) MR, with an annual incidence of 250,000 newly diagnosed patients.

About Evalve, Inc.

Evalve, Inc. (Menlo Park, Calif.) was incorporated in 1999 to design, develop, manufacture, and market innovate devices to enable percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. The company's present development and clinical efforts are focused on mitral valve repair. For more information about Evalve, Inc., and for an animated explanation of the Percutaneous Mitral Repair procedure using the MitraClip device, visit http://www.evalveinc.com. Evalve is the first portfolio company from the medical device company incubator, The Foundry (http://www.thefoundry.com).

MitraClip and Evalve are registered trademarks of Evalve, Inc.

Media Contact:

Heather Harper

Edelman

Cell (415) 533-1001

Office (415) 486-3233

heather.harper@edelman.com


'/>"/>
SOURCE Evalve, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Updated: National Infertility Awareness Week Nov. 4-10; Infertility Affects Significant Number of Couples
2. Evalve(R) Completes $60 Million Series D Financing
3. Eligard(R) six-month formulation successfully completes European approval procedure
4. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
7. GSI Securitization Completes Merger and Domicile Transfer
8. Medical Services International Inc. Completes Testing for European Union (EU) Application
9. Inverness Completes Acquisition of Cholestech
10. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
11. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...Ala., Dec. 2 Southern... organization that conducts basic and applied rese...d development, advanced engineering, environmental...has been awarded a subcontract from Black & Ve...e,s Biological Threat Reduction Program (BTRP) in ...
(Date:12/2/2008)...Dec. 2 What is the T Zo...or mouth. Touching your mucous membranes is how m...k. Touching the T Zone is also referred to as dir...e picking, nail biting and many other descriptors.... habit you will help reduce flu and flu-like illne...
(Date:12/2/2008)...SANTA MONICA, Calif., Dec. 2 /PRNewswire-USNewswir...sent a letter today to President-elect Obama urgin...h care affordable and available by allowing any Am...oup warned Obama that a proposal pushed by health ...y private health insurance policies "amounts only ...
(Date:12/2/2008)...e Health Initiative Will Expand to 70 Cities and R... As the first investment...Johnson Foundation (RWJF) has awarded grants of up...y that will serve as leading sites for its most am...y epidemic. , , Healthy Kids, Healthy Comm...
Breaking Medicine News(10 mins):Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 2Health News:Southern Research Wins $37 Million Black & Veatch Sub-Contract for Biological Threat Reduction Program 3Health News:Dr. Will Sawyer and Henry the Hand Champion Handwasher Have Discovered How to PREVENT the Flu and Common Cold!! DO NOT TOUCH the T Zone! 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 2Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 3Health News:Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity 4
...isphosphonates are at an increased risk of jaw or ...nates are used to treat cancer-related bone lesio...duced bone density. Several recent studies have f...of intravenous bisphosphonates and osteonecrosis o...
...ople have been bitten and injured by a jackal in B...abies vaccines in the government hospitals to trea... has attacked and injured villagers - including wo...villages under the Manjhagarh block of the distric...
...al progress in curbing the spread of polio with ju...r compared to 676 last year, says WHO. Of the 8...m Uttar Pradesh and 17 from Bihar, it says. 'The...polio in 2007 is 213 compared with 585 for the sam...
...n Pakistan, evoking mixed reactions. <brThei...omething extraordinary. Then the Lahore High Cour...omes as a pleasant surprise is the decision of the... Court to release them on bail and hear their app...
Other Medicine News:Health News:Bisphosphonate Increases the Risk of Jaw Bone Deterioration 2Health News:India Records Substantial Decline in Polio Cases 2Health News:Same Sex Pair Get Relief in Pakistan 2
(Date:12/1/2008)...e study shows the Prox1 gene is a two-way switch t...ells to be reprogrammed so that they lose their id...s , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-US...search Hospital have discovered that a certain dif...entity that it requires the constant expression of...
(Date:12/1/2008)...STGARD, Denmark, December 1 /PRNewswire-FirstCall/...07 with the intent to procure an MVA-based,third...ernment Services,Canada, on behalf of the Canadia...ontract to Bavarian Nordic for the delivery of IMV... to use IMVAMUNE(R) as part of the,country,s bio-...
(Date:12/1/2008)...GO, Dec. 1 Vical Incorpo...t of a $1.0 million milestone payment from Merck &... of a Phase I clinical trial of an investigational...vaccine is based on Vical,s DNA gene delivery tech...riptase (hTERT). hTERT is the subject of separate ...
(Date:11/28/2008)...RLITZ, Germany, November 28 German...eadership in specialized HIV monitoring and,AIDS ...merging countries. In,the year 2008, 2.5 million ...le, robust and highly affordable "CyFlow" system, ...ing with HIV/AIDS. Due to introduction of the,Par...
Breaking Medicine Technology:Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Fantastic photographs of fluorescent fish 4890 1Old and new therapies combine to tackle atherosclerosis 7697 1Old and new therapies combine to tackle atherosclerosis 7697 2Old and new therapies combine to tackle atherosclerosis 7697 3Water purification down the nanotubes 7695 1Water purification down the nanotubes 7695 2Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 1Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 2Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 3Cadence Pharmaceuticals Updates Omigard 28TM 29 Clinical Timeline 3058 4
...o Company Oncology Programs to be Presented, SOUTH...-FirstCall/ -- Cytokinetics, Incorporated announce...data will be,presented at the 2007 Annual Meeting ...ACR) to be held from April 14- 18, 2007 in,Los Ang...cology,programs at Cytokinetics and will present d...
...--(BUSINESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline (...DLR) today announced data from Study 767905/014 an...rogram for,alvimopan (Entereg/Entrareg(R))., Study...(12,month) study, was designed to evaluate the lon... twice daily in patients taking,opioids for chroni...
Other Medicine Technology:Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
Wilbrandt-binkhorst irrigating cannula.
Binkhorst, length 18 mm.
Wilbrandt-Binkhorst Cannula have a smooth blunt tip end opening.
Army navy retractor set.
Medicine Products: